How cost-effective is hepatitis C virus treatment for people who inject drugs?

Journal of Gastroenterology and Hepatology (Australia)

Volumn 28, Issue 4, 2013, Pages 590-592

  Martin, Natasha K ^a,b   Vickerman, Peter ^b   Miners, Alec ^b   Hickman, Matthew ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PEGINTERFERON; RIBAVIRIN;

ARTICLE; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; HEALTH CARE COST; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INTRAVENOUS DRUG ABUSE; PRIORITY JOURNAL; QUALITY OF LIFE;

EID: 84875581378     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/jgh.12113     Document Type: Article

References (24)

1. Vickerman P, Martin N, Turner K, Hickman M. Can needle and syringe programmes and opiate substitution therapy achieve substantial reductions in HCV prevalence? Model projections for different epidemic settings. Addiction 2012; 107: 1984-1995.
2. Iverson J, Maher L. Australian Needle and Syringe Program National Data Report 2007-2011. In: The Kirby Institute, ed. University of New South Wales. 2012.
3. Martin NK, Vickerman P, Foster GR etal. Can antiviral therapy for hepatitis C reduce the prevalence of HCV among injecting drug user populations? A modelling analysis of its prevention utility. J. Hepatol. 2011; 54: 1137-1144.
4. Sroczynski G, Esteban E, Conrads-Frank A etal. Long-term effectiveness and cost-effectiveness of antiviral treatment in hepatitis C. J. Viral Hepat. 2010; 17: 34-50.
5. Cammà C, Petta S, Enea M etal. Cost-effectiveness of boceprevir or telaprevir for untreated patients with genotype 1 chronic hepatitis C. Hepatology 2012; 56: 850-860.
6. Liu S, Cipriano LE, Holodniy M, Owens DK, Goldhaber-Fiebert JD. New protease inhibitors for the treatment of chronic hepatitis CA cost-effectiveness analysis. Ann. Intern. Med. 2012; 156: 279-290.
7. Visconti A, Doyle J, Weir A, Shiell A, Hellard M. Assessing the cost-effectiveness of treating chronic hepatitis C virus in people who inject drugs in Australia. J. Gastroenterol. Hepatol. 2013; 28: 707-716.
8. Martin NK, Miners A, Vickerman P etal. The cost-effectiveness of HCV antiviral treatment for injecting drug user populations. Hepatology 2012; 55: 49-57.
9. Sheerin IG, Green FT, Sellman JD. What is the cost-effectiveness of hepatitis C treatment for injecting drug users on methadone maintenance in New Zealand? Drug Alcohol Rev. 2004; 23: 261-272.
10. Thompson Coon J, Castelnuovo E, Pitt M etal. Case finding for hepatitis C in primary care: a cost utility analysis. Fam. Pract. 2006; 23: 393-406.
11. Stein K, Dalziel K, Walker A etal. Screening for Hepatitis C in injecting drug users: a cost utility analysis. J. Public Health 2004; 26: 61-71.
12. Vickerman P, Miners A, Williams J. Assessing the cost-effectiveness of interventions linked to needle and syringe programmes for injecting drug users. In: NICE, ed. London. 2008.
13. Leal P, Stein K, Rosenberg W. What is the cost utility of screening for hepatitis C virus (HCV) in intravenous drug users? J. Med. Screen. 1999; 6: 124-131.
14. Wong JB, Sylvestre Diana L, Siebert U. Cost-effectiveness of treatment of hepatitis C in injecting drug users. In: Jager J, Limburg W, Kretzszschmar M, Postma M, Wiessing L, eds. Hepatitis C and Injecting Drug Use: Impact, Costs and Policy Options. Belgium: European Monitoring Centre for Drugs and Drug Addiction, 2004; 219-244.
15. Postma M, Wiessing L, Jager J. Updated healthcare cost estimtes for drug-related hepatitis C infections in the European Union. In: Jager J, Limburg W, Kretzschmar M, Postma M, Wiessing L, eds. Hepatitis C and Injecting Drug Use: Impact, Costs and Policy Options. Belgium: Eurpean Monitoring Centre for Drug and Drug Addiction, 2004; 203-218.
16. Loubiere S, Rotily M, Moatti J-P. Prevention could be less cost-effective than cure: the case of hepatitis C screening policies in France. Int. J. Technol. Assesses Health Care 2003; 19: 632-645.
17. Grebely J, Raffa JD, Lai C etal. Low uptake of treatment for hepatitis C virus infection in a large community-based study of inner city residents. J. Viral Hepat. 2009; 16: 352-358.
18. Dalgard O. Follow up studies of treatment for hepatitis C virus infection among injection drug users. Clin. Infect. Dis. 2005; 40: S336-S338.
19. Grebely J, Knight E, Ngai T etal. Reinfection with hepatitis C virus following sustained virological response in injection drug users. J. Gastroenterol. Hepatol. 2010; 25: 1281-1284.
20. Hellard M, Sacks-Davis R, Gold J. Hepatitis C treatment for injection drug users: a review of the available evidence. Clin. Infect. Dis. 2009; 49: 561-573.
21. Dore GJ. The changing therapeutic landscape for hepatitis C. Med. J. Aust. 2012; 196: 629-632.
22. Gane EJ, Stedman CA, Hyland RH etal. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N. Engl. J. Med. 2013; 368: 34-44.
23. Poordad F, Lawitz E, Kowdley KV, Cohen DE etal. Exploratory study of oral combination antiviral therapy for hepatitis C. N. Engl. J. Med. 2013; 368: 45-53.
24. Stedman CA. Current prospects for interferon-free treatment of hepatitis C in 2012. J. Gastroentrol. Hepatol. 2013; 28: 38-45.